Anzeige
Mehr »
Login
Donnerstag, 16.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
Letzte Chance, bevor die Bohrer dieses "Monster"-Vorkommen bei einem 13-Millionen-Unternehmen ansteuern
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
340 Leser
Artikel bewerten:
(2)

Prophecy Market Insights: Generic Sterile Injectables Market Projected to Reach US$ 196.2 billion by 2029, Growing at a CAGR of 11.2%

Finanznachrichten News

COVINA, Calif., May 9, 2023 /PRNewswire/ -- According to Prophecy Market Insights "Generic Sterile Injectables Market accounted for US$ 68.7 billion in 2019 and is estimated to be US$196.2 billion by 2029 and is anticipated to register a CAGR of 11.2%"

Prophecy Market Insights Logo


What is the Overview of Generic Sterile Injectables Market?

Generic Sterile Injectable are referred to biologics which are used for treating various drugs and contains same active ingredients as that of branded version. An injectable compounded medication is a sterile drug to be administered into the body using a syringe and needle or an I.V. administration set and needle device.

Growing prevalence of chronic diseases has become major factor in target market growth. Growing number of drug manufacturers focusing on the production of drugs to treat cancer and rapid FDA (Food and Drug Administration) approval of sterile injectable drugs within short period of time is expected to fruitful the demand for Generic Sterile Injectables market growth.

What are the Recent Key Highlights of Generic Sterile Injectables Market?

  • In August 2018, Apotex received FDA (Food and Drug Administration) approval for its generic potassium chloride injection under FDA's CGT (Competitive Generic Therapy) to treat and prevent low potassium blood levels such as hypokalemia.
  • In March 2023, Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces the launch of four new sterile injectable medicines in Canada, providing important new treatment options for patients and health care providers, and building on the company's growing presence in the Canadian market.
  • In March 2023, Milla Pharmaceuticals Inc., a subsidiary of the Alter Pharma Group, announced that its partner, Athenex Pharmaceutical Division (APD), has just started to commercialize its abbreviated new drug application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for its Generic Version of Magnesium Sulfate in Water for Injection, 2 g/50 mL (40 mg/mL), 4 g/100 mL (40 mg/mL) and 4 g/50 mL (80 mg/mL), in Non-PVC, Single-Patient.

Download a Sample Copy of Report:

https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/4277

Who are the Top Key players operating in the Generic Sterile Injectables Market?

  • Sun Pharmaceutical Industries, Ltd.
  • Aspen Pharmacare Holding, Ltd.
  • Lupin Limited
  • Cipla Pharmaceuticals, Inc.
  • Fresenius Kabi
  • AuroMedics Pharma LLC
  • Valeant Pharmaceuticals, Inc.
  • Kay Pharma
  • CSC Pharmaceuticals, Inc.
  • Reddys Laboratories Limited

Report Scope:

Attribute

Details

Base year for estimation

2019

Forecast period

2019 - 2029

Accounted in 2019

68.7 billion

Estimated to be in 2029

US$ 196.2 billion

CAGR

11.2 %

Market representation

Revenue in USD Million & CAGR from 2019 - 2029

Market Segmentation

By Drug type- Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Vaccines, Immunoglobulin, Blood Factors, Antibiotics, and Others

By Therapeutic application- Cancer, Diabetes, Cardiovascular Disease, Central Nervous System, Musculoskeletal System, and Others

By Distribution channel- Hospitals, Drug Stores, and Retail Pharmacies

Regional scope

North America - U.S., Canada

Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe

Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific

Latin America - Brazil, Mexico, Argentina, Rest of Latin America

Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Customization Scope

Avail of customized purchase options to meet your exact research needs.

https://www.prophecymarketinsights.com/market_insight/Insight/request-customization/4277

What is Prophecy's Analyst View on Generic Sterile Injectables Market?

Generic Sterile Injectables has become an important segment of pharmaceutical industry due to growing demand for affordable healthcare which, in turn, facilitated the market growth. Due to its cost-effectiveness and affordable alternative the Generic Sterile Injectables market is likely to expand in coming years.

How did COVID-19 Impact on Generic Sterile Injectables Market?

The COVID-19 pandemic caused disruptions in the global supply chain, resulting in delays in the production and distribution of generic sterile injectables and shortages of some products. However, the increased demand for critical care medications, including sterile injectables, due to the surge in COVID-19 cases created opportunities for manufacturers of generic sterile injectables. Delays in clinical trials for new drugs, including sterile injectables, and a growing focus on ensuring their safety and quality were also observed. The pandemic also led to changes in the prescribing and administration of sterile injectables due to pandemic-related restrictions on hospital visits and procedures.

What are the Possibilities for Generic Sterile Injectables Market?

  • Increasing Demand for Cost-Effective Treatment: With the rising cost of healthcare, patients and healthcare providers are looking for cost-effective treatment options. Generic sterile injectables offer a more affordable alternative to branded products, which is driving demand for these products.
  • Expanding Applications of Sterile Injectables: Sterile injectables are used in the treatment of a wide range of diseases and conditions, and the applications of these products continue to expand. This is creating new opportunities for manufacturers of generic sterile injectables.
  • Growing Number of Patent Expirations: Many patents for branded sterile injectables are set to expire in the coming years, which is creating opportunities for manufacturers of generic products to enter the market. This is expected to increase competition and drive down prices, further boosting demand for generic sterile injectables.
  • Increasing Focus on Quality and Safety: As with all pharmaceutical products, quality and safety are critical concerns for sterile injectables. With growing awareness of these issues, there is an increasing focus on ensuring the quality and safety of generic sterile injectables. This is expected to further boost demand for these products.

What are the Drivers of the Generic Sterile Injectables Market?

  • Increasing prevalence of chronic diseases such as cancer, diabetes, and cardiovascular diseases
  • Rise in demand for cost-effective drugs due to the high cost of branded sterile injectables
  • Need for a reliable supply of drugs, particularly in critical care settings
  • Aging population driving demand for sterile injectables
  • Advancements in drug delivery systems and new technologies creating opportunities for innovation in the generic sterile injectables market.

What are the Restrains of the Generic Sterile Injectables Market?

  • Regulatory challenges: Stringent regulations regarding quality control and safety standards for sterile injectables can make it difficult for manufacturers to launch new products.
  • Patent protection: The patent protection for some sterile injectables can limit the availability of generic alternatives, thereby reducing competition in the market.
  • High development costs: The development of sterile injectables requires significant investment in research and development, which can be a barrier for smaller manufacturers.
  • Supply chain challenges: Any disruptions in the global supply chain can lead to shortages of sterile injectables, resulting in reduced revenue and market growth.
  • Manufacturing complexities: Sterile injectables require specialized manufacturing facilities and processes, which can increase the manufacturing costs and make it difficult for new entrants to compete in the market.

Download PDF Brochure:

https://www.prophecymarketinsights.com/market_insight/Insight/request-pdf/4277

Key questions answered in this report:

  • What is the current size of the generic sterile injectables market, and what is the projected market growth rate?
  • What are the major drivers of growth in the generic sterile injectables market, and what factors are constraining growth?
  • What are the key trends and challenges in the generic sterile injectables market, and how are market participants addressing these challenges?
  • What is the competitive landscape of the generic sterile injectables market, and what are the market shares of key players in the industry?
  • How has the COVID-19 pandemic impacted the demand for generic sterile injectables, and what are the long-term implications for the market?

Report available for Immediate Download:

https://www.prophecymarketinsights.com/market_insight/buy_now/4277?licence=6350&report_type=Generic+Sterile+Injectables+Market&v1_licence_type=press_id

Browse Other Related Research Reports from Prophecy Market Insights:

Active pharmaceutical ingredients (API) market accounted for US$ 164.89 billion in 2020 and is estimated to be US$ 339.08 billion by 2030 and is anticipated to register a CAGR of 7.5%.

India Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market accounted for US$ 1,845.62 million in 2019 and is estimated to be US$ 6,557.05 million by 2030 and is anticipated to register a CAGR of 6.3%.

Small Molecule Prefilled Syringes Market accounted for US$ 18.56 Billon in 2022 and is estimated to be US$ 35.26 by 2032 and is anticipated to register a CAGR of 6.7%.

About Us:

Prophecy Market Insights is a leading provider of market research services, offering insightful and actionable reports to clients across various industries. With a team of experienced analysts and researchers, Prophecy Market Insights provides accurate and reliable market intelligence, helping businesses make informed decisions and stay ahead of the competition. The company's research reports cover a wide range of topics, including industry trends, market size, growth opportunities, competitive landscape, and more. Prophecy Market Insights is committed to delivering high-quality research services that help clients achieve their strategic goals and objectives.

To know more
Contact Us:
Sales
Prophecy Market Insights
?? US toll free: +1 860 531 2574
?? Rest of world: + 91 7775049802
? Email- sales@prophecymarketinsights.com
?? Website- www.prophecymarketinsights.com
Follow us on:
LinkedIn | Twitter | Facebook |Youtube

Logo: https://mma.prnewswire.com/media/2067755/Prophecy_Market_Insights_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/generic-sterile-injectables-market-projected-to-reach-us-196-2-billion-by-2029--growing-at-a-cagr-of-11-2-301819385.html

© 2023 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.